查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869686

疼痛管理藥物市場規模、佔有率和趨勢分析報告：按藥物類別、適應症、分銷管道、地區和細分市場預測（2025-2033 年）

Pain Management Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

疼痛管理藥物市場摘要

2024年全球疼痛管理藥物市場規模估計為788.4億美元，預計2033年將達到1,159.2億美元。

預計從 2025 年到 2033 年，全球疼痛管理藥物市場將以 4.38% 的複合年成長率成長。人口老化和生活方式相關因素導致慢性疼痛疾病盛行率上升，推動了全球疼痛管理藥物市場的成長。

關節炎、癌症相關疼痛、腰背部疾病、神經病變疼痛和術後疼痛的日益普遍，推動了對有效藥物介入的需求。肌肉骨骼和神經系統疾病負擔的加重，使得需要長期疼痛治療的患者群體不斷擴大。醫療機構正在採用先進的疼痛管理方法，以提高患者的生活品質並減輕醫療負擔。此外，人們越來越認知到疼痛是一種可治療的臨床疾病，這促使疼痛的早期診斷和治療。全球外科手術數量的增加也導致止痛藥和鴉片類藥物的消費量增加，凸顯了針對性強、多方面的疼痛管理療法的必要性。

非鴉片類鎮痛藥和新型藥物遞送技術的持續創新正進一步推動市場擴張。例如，2025年1月，《時代》雜誌報道稱，美國食品藥物管理局（FDA）核准了由Vertex Pharmaceuticals公司以“Journavx”為商品名銷售的舒澤替啶（suzetridine），這是20多年來首個獲批的新型非鴉片類鎮痛藥。舒澤替啶是一種50毫克的口服錠劑，每日服用兩次，其作用標靶是疼痛神經元特異性的Nav1.8鈉通道，從而避免了鴉片類藥物的成癮性。在拇趾滑液囊炎手術和腹部整形術後患者的臨床試驗中，舒澤替啶組分別有83%和61%的參與者報告疼痛減輕30%或更多，而安慰劑組的相應比例分別為68%和48%。這些結果表明，舒澤替啶可能是治療急性疼痛的一種比鴉片類藥物更安全的選擇。製藥公司也致力於開發更安全的配方，緩釋性和經皮製劑的進步正在提高療效、便利性和患者依從性。

監管審查持續影響市場趨勢。例如，2025年3月12日，英國藥品和保健產品監管局（MHRA）和藥品委員會（CHM）發布了一份詳細報告，宣布由於安全隱患，包括持續性術後鴉片類藥物使用（PPOU）和鴉片類藥物引起的呼吸功能障礙（OIVI），所有緩釋性鴉片類藥物製劑均不再用於術後鎮痛。 PPOU發生率在接受長效鴉片類藥物治療的患者為2%至44%，在先前使用過該藥物的患者中高達60%。 OIVI的發生率介於0.4%至41%之間。針對這些發現，MHRA建議僅使用速效鴉片類藥物進行短期術後鎮痛治療，並鼓勵採用小容量包裝以減少過度處方。總體而言，非成癮性鎮痛藥、個人化治療、數位監測工具和擴大醫療保健服務範圍的研究和開發進展，正在推動全球疼痛管理市場的持續成長。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 疼痛管理藥物市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 定價分析

第4章 疼痛管理藥物市場：依藥物類別進行業務分析

  • 2024 年及 2033 年市佔率
  • 細分儀表板
  • 按藥物類別分類的市場規模、預測和趨勢分析，2021-2033年
  • NSAIDs
  • 鴉片類藥物
  • 麻醉劑
  • 抗憂鬱症
  • 抗驚厥藥
  • 其他

第5章 疼痛管理藥物市場：按適應症分類的業務分析

  • 2024 年及 2033 年市佔率
  • 細分儀表板
  • 市場規模、預測與趨勢分析（按指標，2021-2033 年）
  • 急性疼痛（術後、創傷相關、肌肉骨骼疼痛）
  • 慢性肌肉骨骼疼痛/骨關節炎/下背痛
  • 神經病變疼痛（糖尿病神經病變、帶狀皰疹後遺症神經痛、纖維肌痛）
  • 偏頭痛（急性期和預防期）
  • 癌症疼痛
  • 手術/住院治療後引起的疼痛（短期）
  • 其他

第6章：疼痛管理藥物市場：按分銷管道分類的業務分析

  • 2024 年及 2033 年市佔率
  • 細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析，2021-2033年
  • 網路藥房
  • 零售藥房
  • 醫院藥房

第7章：疼痛管理藥物市場：區域估算與趨勢分析

  • 2024 年及 2033 年市佔率分析
  • 市場儀錶板
  • 2021-2033年各地區市場規模及預測趨勢分析
  • 北美洲
    • 按國家/地區分類，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Teva Pharmaceutical
    • Pfizer
    • Abbott
    • Mallinckrodt Pharmaceuticals
    • Endo International
    • GlaxoSmithKline
    • AstraZeneca
    • Depomed
    • Merck
    • Novartis
Product Code: GVR-4-68040-779-0

Pain Management Drugs Market Summary

The global pain management drugs market size was estimated at USD 78.84 billion in 2024 and is projected to reach USD 115.92 billion by 2033, growing at a CAGR of 4.38% from 2025 to 2033. The rising prevalence of chronic pain conditions across aging and lifestyle-affected populations drives the growth of the global pain management drugs market.

Increasing cases of arthritis, cancer-related pain, lower back disorders, neuropathic pain, and post-surgical discomfort have intensified the demand for effective pharmacological interventions. The growing burden of musculoskeletal and neurological disorders has expanded the patient pool requiring long-term pain therapy. Healthcare providers are adopting advanced pain management approaches to enhance quality of life and reduce healthcare burden. In addition, the growing awareness of pain as a treatable clinical condition has supported early diagnosis and treatment. The rising number of surgical procedures globally further contributes to the higher consumption of analgesics and opioids, strengthening the need for targeted and multimodal pain management therapies.

The market expansion is further supported by continuous innovation in non-opioid pain medications and novel drug delivery technologies. For instance, in January 2025, TIME reported that the U.S. Food and Drug Administration (FDA) approved suzetrigine, marketed as Journavx by Vertex Pharmaceuticals, as the first new class of non-opioid pain medication in over 20 years. Suzetrigine is a 50 mg oral tablet taken twice daily and targets the Nav1.8 sodium channel, specific to pain neurons, thereby avoiding the addictive potential of opioids. In clinical trials involving patients recovering from bunionectomy and abdominoplasty surgeries, 83% and 61% of participants taking suzetrigine, respectively, reported at least a 30% reduction in pain, compared to 68% and 48% in the placebo groups. These results suggest that suzetrigine may offer a safer alternative to opioids for managing acute pain. Pharmaceutical companies also focus on developing safer formulations, while advancements in extended-release and transdermal drugs improve efficacy, convenience, and patient adherence.

Regulatory oversight continues to shape market trends. For instance, on March 12, 2025, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicines (CHM) published a report detailing the removal of the post-operative pain indication from all modified-release opioids due to safety concerns, including persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI). PPOU occurred in 2% to 44% of patients treated with prolonged-release opioids, rising to 60% in those previously using these opioids, while OIVI incidence ranged from 0.4% to 41%. Consequently, the MHRA recommended that only immediate-release opioids be prescribed for short-term post-operative pain and encouraged smaller pack sizes to reduce over-prescription. Overall, growing R&D in non-addictive analgesics, personalized therapies, digital monitoring tools, and expanded healthcare access is fueling the sustained growth of the pain management drugs market globally.

Global Pain Management Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pain management drugs market report based on drug class, indication, distribution channel and region:

  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • NSAIDs
  • Opioids
  • Anesthetics
  • Antidepressants
  • Anticonvulsants
  • Others
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Acute Pain (Postoperative, Injury-Related, Musculoskeletal)
  • Chronic Musculoskeletal Pain / Osteoarthritis / Low Back Pain
  • Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia)
  • Migraine (Acute & Preventive)
  • Cancer Pain
  • Post-Surgical / Hospital-Based Procedural Pain (short duration)
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Online Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pain Management Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Pricing Analysis

Chapter 4. Pain Management Drugs Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 4.4. NSAIDs
    • 4.4.1. NSAIDs Market, 2021 - 2033 (USD Million)
  • 4.5. Opioids
    • 4.5.1. Opioids Market, 2021 - 2033 (USD Million)
  • 4.6. Anesthetics
    • 4.6.1. Anesthetics Market, 2021 - 2033 (USD Million)
  • 4.7. Antidepressants
    • 4.7.1. Antidepressants Market, 2021 - 2033 (USD Million)
  • 4.8. Anticonvulsants
    • 4.8.1. Anticonvulsants Market, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Pain Management Drugs Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 5.4. Acute Pain (Postoperative, Injury-Related, Musculoskeletal)
    • 5.4.1. Acute Pain (Postoperative, Injury-Related, Musculoskeletal) Market, 2021 - 2033 (USD Million)
  • 5.5. Chronic Musculoskeletal Pain / Osteoarthritis / Low Back Pain
    • 5.5.1. Chronic Musculoskeletal Pain / Osteoarthritis / Low Back Pain Market, 2021 - 2033 (USD Million)
  • 5.6. Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia)
    • 5.6.1. Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia) Market, 2021 - 2033 (USD Million)
  • 5.7. Migraine (Acute & Preventive)
    • 5.7.1. Migraine (Acute & Preventive) Market, 2021 - 2033 (USD Million)
  • 5.8. Cancer Pain
    • 5.8.1. Cancer Pain Market, 2021 - 2033 (USD Million)
  • 5.9. Post-Surgical / Hospital-Based Procedural Pain (short duration)
    • 5.9.1. Post-Surgical / Hospital-Based Procedural Pain (short duration) Market, 2021 - 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Pain Management Drugs Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.4. Online Pharmacy
    • 6.4.1. Online Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.6. Hospital Pharmacy
    • 6.6.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)

Chapter 7. Pain Management Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Pain Management Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Teva Pharmaceutical
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Pfizer
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Abbott
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Mallinckrodt Pharmaceuticals
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Endo International
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. GlaxoSmithKline
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. AstraZeneca
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Depomed
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Merck
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Novartis
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global pain management drugs market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 5 Global pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 6 Global pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America pain management drugs market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 9 North America pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 10 North America pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 12 U.S. pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 13 U.S. pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 15 Canada pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 16 Canada pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 18 Mexico pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 19 Mexico pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe pain management drugs market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 22 Europe pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 23 Europe pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 25 UK pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 26 UK pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 28 Germany pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 29 Germany pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 31 France pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 32 France pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 34 Italy pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 35 Italy pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 37 Spain pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 38 Spain pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 40 Norway pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 41 Norway pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 43 Denmark pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 44 Denmark pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 46 Sweden pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 47 Sweden pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific pain management drugs market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific pain management drugs market, by distribution channel, 2021 - 2033 (USD
  • Table 52 Japan pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 53 Japan pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 54 Japan pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 56 China pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 57 China pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 59 India pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 60 India pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 62 Australia pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 63 Australia pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 65 South Korea pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 66 South Korea pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 68 Thailand pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 69 Thailand pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America pain management drugs market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 72 Latin America pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 73 Latin America pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 75 Brazil pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 76 Brazil pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 78 Argentina pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 79 Argentina pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Pain management drugs market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 85 South Africa pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 86 South Africa pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 91 UAE pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 92 UAE pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 94 Kuwait pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 95 Kuwait pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Pain management drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and drug class outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Pain management drugs market dynamics
  • Fig. 12 Pain management drugs market: Porter's five forces analysis
  • Fig. 13 Pain management drugs market: PESTLE analysis
  • Fig. 14 Drug class market, 2021 - 2033 (USD Million)
  • Fig. 15 NSAIDs market, 2021 - 2033 (USD Million)
  • Fig. 16 Opioids market, 2021 - 2033 (USD Million)
  • Fig. 17 Anesthetics market, 2021 - 2033 (USD Million)
  • Fig. 18 Antidepressants market, 2021 - 2033 (USD Million)
  • Fig. 19 Anticonvulsants market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 Indication market, 2021 - 2033 (USD Million)
  • Fig. 22 Acute Pain (Postoperative, Injury-Related, Musculoskeletal) market, 2021 - 2033 (USD Million)
  • Fig. 23 Chronic Musculoskeletal Pain / Osteoarthritis / Low Back Pain market, 2021 - 2033 (USD Million)
  • Fig. 24 Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia) market, 2021 - 2033 (USD Million)
  • Fig. 25 Migraine (Acute & Preventive) market, 2021 - 2033 (USD Million)
  • Fig. 26 Cancer Pain market, 2021 - 2033 (USD Million)
  • Fig. 27 Post-Surgical / Hospital-Based Procedural Pain (short duration) market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 30 Online pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 31 Retail pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 32 Hospital pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 33 Pain management drugs market revenue, by region
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 36 U.S. country dynamics
  • Fig. 37 U.S. pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 38 Canada country dynamics
  • Fig. 39 Canada pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 40 Mexico country dynamics
  • Fig. 41 Mexico pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 42 Europe pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 43 UK country dynamics
  • Fig. 44 UK pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 45 Germany country dynamics
  • Fig. 46 Germany pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 47 France country dynamics
  • Fig. 48 France pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 49 Italy country dynamics
  • Fig. 50 Italy pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 51 Spain country dynamics
  • Fig. 52 Spain pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 53 Norway country dynamics
  • Fig. 54 Norway pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 55 Sweden country dynamics
  • Fig. 56 Sweden pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 57 Denmark country dynamics
  • Fig. 58 Denmark pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 59 Asia Pacific pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 60 Japan country dynamics
  • Fig. 61 Japan pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 62 China country dynamics
  • Fig. 63 China pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 64 India country dynamics
  • Fig. 65 India pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 66 Australia country dynamics
  • Fig. 67 Australia pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 68 South Korea country dynamics
  • Fig. 69 South Korea pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 70 Thailand country dynamics
  • Fig. 71 Thailand pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 72 Latin America pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 73 Brazil country dynamics
  • Fig. 74 Brazil pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 75 Argentina country dynamics
  • Fig. 76 Argentina pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 77 MEA pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 78 South Africa country dynamics
  • Fig. 79 South Africa pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 80 Saudi Arabia country dynamics
  • Fig. 81 Saudi Arabia pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 82 UAE country dynamics
  • Fig. 83 UAE pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 84 Kuwait country dynamics
  • Fig. 85 Kuwait pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 86 Company categorization
  • Fig. 87 Company market position analysis
  • Fig. 88 Strategic framework